<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04551729</url>
  </required_header>
  <id_info>
    <org_study_id>75112</org_study_id>
    <nct_id>NCT04551729</nct_id>
  </id_info>
  <brief_title>Fluid Restriction in Heart Failure Versus Liberal Fluid Uptake</brief_title>
  <acronym>FRESH-UP</acronym>
  <official_title>Fluid Restriction in Heart Failure Versus Liberal Fluid Uptake</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-centre open-label 1:1 randomized clinical trial in chronic heart failure patients on&#xD;
      the effect of fluid restriction versus liberal fluid intake on quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The members of the event adjudication committee will be blinded for treatment allocation. Moreover, the statistician who performs the primary analysis will be blinded for treatment allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life assessed with the Kansas City Cardiomyopathy Questionnaire (scores minimum-maximum 0-100)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">498</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Fluid restriction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive a lifestyle advice to adhere to fluid restriction of 1500cc/day for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liberal fluid intake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive a lifestyle advice for liberal fluid intake for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle advice for liberal fluid intake</intervention_name>
    <description>Lifestyle advice for liberal fluid intake for 3 months</description>
    <arm_group_label>Fluid restriction</arm_group_label>
    <arm_group_label>Liberal fluid intake</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of chronic HF with NYHA class II/III according to the prevailing guidelines&#xD;
             &gt; 6 months prior to randomization (1)&#xD;
&#xD;
          -  Adult (age â‰¥ 18 years)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Reversible cause of HF (thyroid disorders, severe anemia, vitamin deficiencies)&#xD;
&#xD;
          -  Hopital admission for HF within 3 months of randomization&#xD;
&#xD;
          -  Chronic HF with NYHA class IV&#xD;
&#xD;
          -  Hyponatremia at baseline (sodium &lt;130mmol/l)&#xD;
&#xD;
          -  Estimated Glomerular Filtration Rate (eGFR) of &lt; 30ml/min/1.73 m2 at baseline&#xD;
&#xD;
          -  Scheduled cardiac surgery within 3 months of randomization&#xD;
&#xD;
          -  Recent (within 3 months) coronary intervention (PCI or CABG) or implantation of&#xD;
             pacemaker device&#xD;
&#xD;
          -  Comorbidity for which fluid restriction is advised by a different treating physician&#xD;
             (e.g. nephrologist)&#xD;
&#xD;
          -  Comorbidity with a life expectancy of less than 6 months&#xD;
&#xD;
          -  The treating clinician believes that participation in the domain would not be in the&#xD;
             best interests of the patient&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland van Kimmenade, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roland van Kimmenade, MD PhD</last_name>
    <phone>+31-24-3616785</phone>
    <email>roland.vankimmenade@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frank Gommans, MD PhD</last_name>
    <phone>+31-24-3616785</phone>
    <email>Frank.gommans@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland RJ van Kimmenade, MD PhD</last_name>
      <phone>+31-24-3616785</phone>
      <email>roland.vankimmenade@radboudumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Other investigators can submit a proposal to the steering committee for the sharing of data.&#xD;
This proposal will be discussed in the steering committee.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Weeks</ipd_time_frame>
    <ipd_access_criteria>These will be determined by the steering committee.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

